Stelara Clears FDA; Different Mechanism of Action, But REMS Looks Similar To TNF Class
This article was originally published in The Pink Sheet Daily
Centocor's newest anti-inflammatory biologic - ustekinumab - actually has a different mechanism than the TNF inhibitors, but FDA has the sponsor using a risk management program similar to existing TNF drugs.
You may also be interested in...
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.
Ustekinumab “complete response” letter requests medication guide and communication plan, but not restricted distribution.
New survey shows doctors are warming to another rival, Humira.